Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Guerbet

BATS-CHIXE:GBTP
Snowflake Description

Very undervalued with adequate balance sheet and pays a dividend.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GBTP
BATS-CHIXE
€360M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide. The last earnings update was 14 days ago. More info.


Add to Portfolio Compare Print
  • Guerbet has significant price volatility in the past 3 months.
GBTP Share Price and Events
7 Day Returns
2.3%
BATS-CHIXE:GBTP
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
-48%
BATS-CHIXE:GBTP
-0.3%
GB Medical Equipment
-23.6%
GB Market
GBTP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Guerbet (GBTP) 2.3% -7% -34.2% -48% -62.9% -22.2%
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • GBTP underperformed the Medical Equipment industry which returned -0.3% over the past year.
  • GBTP underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
GBTP
Industry
5yr Volatility vs Market

GBTP Value

 Is Guerbet undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Guerbet to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Guerbet.

BATS-CHIXE:GBTP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.5%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:GBTP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 6.1%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.808 (1 + (1- 33%) (120.64%))
1.309
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (1.309 * 6.07%)
8.47%

Discounted Cash Flow Calculation for BATS-CHIXE:GBTP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Guerbet is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:GBTP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.47%)
2020 39.72 Analyst x5 36.62
2021 47.80 Analyst x4 40.62
2022 52.98 Est @ 10.84% 41.51
2023 57.08 Est @ 7.74% 41.23
2024 60.27 Est @ 5.58% 40.13
2025 62.72 Est @ 4.07% 38.50
2026 64.60 Est @ 3% 36.56
2027 66.06 Est @ 2.26% 34.47
2028 67.21 Est @ 1.74% 32.33
2029 68.14 Est @ 1.38% 30.21
Present value of next 10 years cash flows €372.00
BATS-CHIXE:GBTP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €68.14 × (1 + 0.53%) ÷ (8.47% – 0.53%)
€862.43
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €862.43 ÷ (1 + 8.47%)10
€382.39
BATS-CHIXE:GBTP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €372.00 + €382.39
€754.39
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €754.39 / 12.58
€59.99
BATS-CHIXE:GBTP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:GBTP represents 1.00349x of ENXTPA:GBT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.00349x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 59.99 x 1.00349
€60.20
Value per share (EUR) From above. €60.20
Current discount Discount to share price of €28.70
= -1 x (€28.70 - €60.20) / €60.20
52.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Guerbet is available for.
Intrinsic value
>50%
Share price is €28.7 vs Future cash flow value of €60.2
Current Discount Checks
For Guerbet to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Guerbet's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Guerbet's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Guerbet's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Guerbet's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:GBTP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €3.45
ENXTPA:GBT Share Price ** ENXTPA (2020-04-07) in EUR €28.6
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Guerbet.

BATS-CHIXE:GBTP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:GBT Share Price ÷ EPS (both in EUR)

= 28.6 ÷ 3.45

8.29x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Guerbet is good value based on earnings compared to the GB Medical Equipment industry average.
  • Guerbet is good value based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Guerbet's expected growth come at a high price?
Raw Data
BATS-CHIXE:GBTP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 8.29x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
14%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:GBTP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 8.29x ÷ 14%

0.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Guerbet is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Guerbet's assets?
Raw Data
BATS-CHIXE:GBTP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €29.27
ENXTPA:GBT Share Price * ENXTPA (2020-04-07) in EUR €28.6
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:GBTP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:GBT Share Price ÷ Book Value per Share (both in EUR)

= 28.6 ÷ 29.27

0.98x

* Primary Listing of Guerbet.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Guerbet is good value based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Guerbet's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Guerbet has a total score of 6/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

GBTP Future Performance

 How is Guerbet expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Guerbet expected to grow at an attractive rate?
  • Guerbet's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Guerbet's earnings growth is positive but not above the United Kingdom of Great Britain and Northern Ireland market average.
  • Guerbet's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:GBTP Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:GBTP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 14%
BATS-CHIXE:GBTP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 2.7%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:GBTP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:GBTP Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 862 110 49 4
2020-12-31 835 102 39 6
2020-04-07
BATS-CHIXE:GBTP Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 817 37
2019-09-30 812 40
2019-06-30 807 88 43
2019-03-31 801 83 45
2018-12-31 795 77 47
2018-09-30 793 68 46
2018-06-30 790 59 46
2018-03-31 800 58 46
2017-12-31 809 56 46
2017-09-30 807 46 43
2017-06-30 805 35 40
2017-03-31 791 37 34

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Guerbet's earnings are expected to grow by 14% yearly, however this is not considered high growth (20% yearly).
  • Guerbet's revenue is expected to grow by 2.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:GBTP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Guerbet Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:GBTP Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 3.90 4.84 2.71 3.00
2020-12-31 2.97 3.97 2.30 5.00
2020-04-07
BATS-CHIXE:GBTP Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31
2019-09-30
2019-06-30 3.45
2019-03-31 3.59
2018-12-31 3.72
2018-09-30 3.68
2018-06-30 3.63
2018-03-31 3.66
2017-12-31 3.69
2017-09-30 3.44
2017-06-30 3.18
2017-03-31 2.76

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Guerbet is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Guerbet's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Guerbet has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

GBTP Past Performance

  How has Guerbet performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Guerbet's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Guerbet's year on year earnings growth rate has been positive over the past 5 years.
  • Guerbet's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Guerbet's 1-year earnings growth is negative, it can't be compared to the GB Medical Equipment industry average.
Earnings and Revenue History
Guerbet's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Guerbet Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:GBTP Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 816.90 37.30
2019-09-30 811.76 40.37 234.76
2019-06-30 806.62 43.44 469.52
2019-03-31 800.61 45.13 463.46
2018-12-31 794.61 46.82 457.40
2018-09-30 792.54 46.18 456.35
2018-06-30 790.47 45.55 455.31
2018-03-31 799.55 45.88 453.38
2017-12-31 808.63 46.22 451.46
2017-09-30 806.91 43.05 447.88
2017-06-30 805.19 39.89 444.31
2017-03-31 790.83 34.41 437.64
2016-12-31 776.47 28.93 430.98
2016-09-30 709.09 29.90 398.30
2016-06-30 641.70 30.87 365.62
2016-03-31 565.81 35.05 318.65
2015-12-31 489.91 39.23 271.68
2015-09-30 462.45 36.90 256.37
2015-06-30 434.99 34.57 241.06
2015-03-31 422.25 30.35 234.67
2014-12-31 409.51 26.13 228.27
2014-09-30 404.87 24.33 226.10
2014-06-30 400.23 22.53 223.94
2014-03-31 395.41 21.51 222.88
2013-12-31 390.60 20.49 221.83
2013-09-30 394.48 18.54 221.26
2013-06-30 398.37 16.60 220.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Guerbet has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Guerbet used its assets less efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Guerbet's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Guerbet's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Guerbet has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

GBTP Health

 How is Guerbet's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Guerbet's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Guerbet is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Guerbet's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Guerbet's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Guerbet Company Filings, last reported 3 months ago.

BATS-CHIXE:GBTP Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31
2019-09-30 367.88 433.91 141.83
2019-06-30 367.88 415.72 141.83
2019-03-31 367.88 415.72 141.83
2018-12-31 366.76 410.81 106.76
2018-09-30 366.76 410.81 106.76
2018-06-30 346.40 414.87 147.79
2018-03-31 346.40 414.87 147.79
2017-12-31 342.14 349.90 75.39
2017-09-30 342.14 349.90 75.39
2017-06-30 324.02 362.45 133.60
2017-03-31 324.02 362.45 133.60
2016-12-31 314.80 395.42 96.55
2016-09-30 314.80 395.42 96.55
2016-06-30 297.02 365.55 134.36
2016-03-31 297.02 365.55 134.36
2015-12-31 282.44 339.92 54.39
2015-09-30 282.44 339.92 54.39
2015-06-30 274.28 65.27 40.47
2015-03-31 274.28 65.27 40.47
2014-12-31 259.10 77.87 20.40
2014-09-30 259.10 77.87 20.40
2014-06-30 247.11 92.37 34.29
2014-03-31 247.11 92.37 34.29
2013-12-31 238.26 97.55 18.43
2013-09-30 238.26 97.55 18.43
2013-06-30 228.97 111.38 35.80
  • Guerbet's level of debt (113%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (30.1% vs 113% today).
  • Debt is well covered by operating cash flow (21.3%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 11.5x coverage).
X
Financial health checks
We assess Guerbet's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Guerbet has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

GBTP Dividends

 What is Guerbet's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.97%
Current annual income from Guerbet dividends. Estimated to be 2.71% next year.
If you bought €2,000 of Guerbet shares you are expected to receive €59 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Guerbet's pays a higher dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.59%).
  • Guerbet's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.08%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:GBTP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:GBTP Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.82 4.00
2020-12-31 0.73 5.00
2020-04-07
BATS-CHIXE:GBTP Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-03-24 0.850 3.014
2019-04-18 0.850 1.889
2018-04-26 0.850 1.529
2018-03-28 0.850 1.415
2017-04-06 0.850 1.113
2017-03-29 0.850 1.082
2016-04-22 0.650 1.021
2015-04-13 0.500 0.920
2014-04-11 0.500 1.444
2014-03-13 0.500 1.541
2013-04-16 0.500 1.956
2013-03-06 0.500 1.825
2012-04-16 0.450 2.302
2012-03-07 0.450 2.418
2011-04-11 0.450 2.581
2011-03-02 0.450 2.718
2010-04-01 0.563 2.987
2009-06-24 0.563 2.218

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Guerbet's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (4.1x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (4.5x coverage).
X
Income/ dividend checks
We assess Guerbet's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Guerbet afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Guerbet has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

GBTP Management

 What is the CEO of Guerbet's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Hale
AGE 50
TENURE AS CEO 0.3 years
CEO Bio

Mr. David Hale has been Chief Executive Officer of Guerbet SA since January 1, 2020. Mr. Hale served as Chief Commercial Officer of Guerbet SA since 2019 until January 1, 2020 and served as its Chief Commercial Officer of Diagnostic Imaging from February 2018 to 2019. Mr. Hale joined Guerbet after 17 years at General Electric Healthcare, where he was President, Enterprise Imaging and Care Area Software Solutions, after holding various commercial, marketing and development positions at regional and then global level. Prior to Guerbet, David Hale was with the Boston Consulting Group. He graduated in industrial and systems engineering from the Georgia Institute of Technology (United States). He also has an MBA from the IMD Business School (Lausanne, Switzerland).

CEO Compensation
  • Insufficient data for David to compare compensation growth.
  • Insufficient data for David to establish whether their remuneration is reasonable compared to companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Guerbet management team in years:

1.8
Average Tenure
50
Average Age
  • The average tenure for the Guerbet management team is less than 2 years, this suggests a new team.
Management Team

Pierre André

TITLE
Deputy CEO & Chief Pharmacist
COMPENSATION
€237K
AGE
50
TENURE
4 yrs

David Hale

TITLE
Chief Executive Officer
AGE
50
TENURE
0.3 yrs

Jérôme Estampes

TITLE
Chief Financial Officer
TENURE
1 yrs

Elena Puntorieri

TITLE
Vice President of Purchasing & Member of Management Board

Anne-Laure Delasalle

TITLE
Vice President of Communications & Image

Antoine Mazraani

TITLE
VP of European Operations & Member of Management Board

Alain Le Jeune

TITLE
Member of Management Board

Frédéric Duchet

TITLE
Chief Information Officer & Member of Management Board

Jean-Rémy Touze

TITLE
Vice President of Human Resources

François Nicolas

TITLE
Chief Digital Officer and VP of Contrast Injection Systems R&D
AGE
48
TENURE
2.6 yrs
Board of Directors Tenure

Average tenure and age of the Guerbet board of directors in years:

5.9
Average Tenure
58
Average Age
  • The tenure for the Guerbet board of directors is about average.
Board of Directors

Marie-Claire Janailhac-Fritsch

TITLE
Chairwoman of the Board
COMPENSATION
€124K
AGE
64
TENURE
6.6 yrs

Michel Guerbet

TITLE
Honorary Chairman
COMPENSATION
€19K

Marion Barbier

TITLE
Non-Independent Director
COMPENSATION
€24K
AGE
61
TENURE
8.8 yrs

Didier Izabel

TITLE
Independent Director
COMPENSATION
€38K
AGE
64
TENURE
5.9 yrs

Thibault Viort

TITLE
Independent Director
COMPENSATION
€26K
AGE
47
TENURE
2.9 yrs

Claire Jouault-Massiot

TITLE
Non-Independent Director
COMPENSATION
€27K
AGE
58
TENURE
6.9 yrs

Mark Fouquet

TITLE
Non-Independent Director
COMPENSATION
€26K
AGE
60
TENURE
5.9 yrs

Céline Lamort

TITLE
Non-Independent Director
COMPENSATION
€23K
AGE
37
TENURE
4.9 yrs

Nicolas Louvet

TITLE
Non-Independent Director
COMPENSATION
€24K
AGE
43
TENURE
3.9 yrs

Eric Guerbet

TITLE
Non-Independent Director
COMPENSATION
€23K
AGE
43
TENURE
2.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Guerbet's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Guerbet has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

GBTP News

Simply Wall St News

GBTP Company Info

Description

Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide. Its products for the CT and Cath Lab examinations include Optiray, a low osmolar contrast medium; Xenetix, a low-osmolar iodinated agent; Telebrix, a high osmolar contrast medium; Conray and MD high osmolar contrast medium products; and high osmolar contrast medium, an ionic low osmolar contrast medium agent. The company’s products for the magnetic resonance imaging (MRI) examinations comprise Dotarem, a non-specific gadolinium-based contrast medium; Artirem products; and Optimark, a contrast medium. In addition, it provides products for interventional imaging, including Lipiodol ethyl esters of iodinated fatty acids of poppy seed oil; Vectorio, a classic transarterial chemoembolization mixing and injection system; and Patent Blue V, an injectable medium. Further, the company offers delivery systems and services comprising injectors; consumables for various types of injectors; and Contrast&Care, a patient data management software. The company distributes its products directly, as well as through distributors and license-holders primarily to hospitals, clinics, radiology centers, purchasing pools, and wholesalers. Guerbet SA was founded in 1926 and is headquartered in Villepinte, France.

Details
Name: Guerbet SA
GBTP
Exchange: BATS-CHIXE
Founded: 1926
€359,658,670
12,575,478
Website: http://www.guerbet.com
Address: Guerbet SA
15, rue des Vanesses,
Zone Paris Nord II,
Villepinte,
Ile-de-France, 93420,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA GBT Ordinary Shares Euronext Paris FR EUR 02. Jan 1992
OTCPK GUER.F Ordinary Shares Pink Sheets LLC US USD 02. Jan 1992
DB 4G8 Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
LSE 0ELV Ordinary Shares London Stock Exchange GB EUR 02. Jan 1992
BATS-CHIXE GBTP Ordinary Shares BATS 'Chi-X Europe' GB EUR 02. Jan 1992
ENXTPA GBTNV EUR1 (RFD 01/01/2020) Euronext Paris FR EUR 02. Jan 2020
Number of employees
Current staff
Staff numbers
2,850
Guerbet employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 22:43
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/03/24
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.